1. Home
  2. ROST vs REGN Comparison

ROST vs REGN Comparison

Compare ROST & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ross Stores Inc.

ROST

Ross Stores Inc.

HOLD

Current Price

$208.83

Market Cap

68.9B

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$738.35

Market Cap

79.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROST
REGN
Founded
1982
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.9B
79.4B
IPO Year
1994
1995

Fundamental Metrics

Financial Performance
Metric
ROST
REGN
Price
$208.83
$738.35
Analyst Decision
Buy
Buy
Analyst Count
17
24
Target Price
$204.25
$819.54
AVG Volume (30 Days)
2.4M
499.4K
Earning Date
03-03-2026
04-28-2026
Dividend Yield
0.86%
0.51%
EPS Growth
13.67
8.19
EPS
4.61
41.48
Revenue
$21,129,219,000.00
$5,872,227,000.00
Revenue This Year
$9.43
$11.69
Revenue Next Year
$6.25
$10.06
P/E Ratio
$45.15
$17.95
Revenue Growth
3.69
20.82
52 Week Low
$122.36
$476.49
52 Week High
$216.80
$821.11

Technical Indicators

Market Signals
Indicator
ROST
REGN
Relative Strength Index (RSI) 57.24 40.83
Support Level $177.85 $731.65
Resistance Level $216.80 $788.69
Average True Range (ATR) 4.33 19.68
MACD -0.79 -4.08
Stochastic Oscillator 63.95 5.12

Price Performance

Historical Comparison
ROST
REGN

About ROST Ross Stores Inc.

Ross Stores, founded in 1982, is a US-focused off-price apparel and home fashion retailer operating more than 2,100 stores across 43 states, primarily under the Ross Dress for Less banner, with a smaller footprint through DD's Discounts. In fiscal 2024, the company generated over $21 billion in sales. Ross offers branded apparel, footwear, accessories, and home goods at a 20%-60% discount to department and specialty store prices, sourcing closeouts and excess inventory from vendors worldwide.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: